Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Dementia01:30

Dementia

702
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
702
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Neural Regulation01:37

Neural Regulation

44.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.8K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.

Brain : a journal of neurology·2021
Same author

The contribution of behavioral features to caregiver burden in FTLD spectrum disorders.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Posterior cortical atrophy phenotypic heterogeneity revealed by decoding <sup>18</sup>F-FDG-PET.

Brain communications·2021
Same author

The temporal onset of the core features in dementia with Lewy bodies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder.

Journal of Parkinson's disease·2021
Same author

Regional Brain Stiffness Analysis of Dementia with Lewy Bodies.

Journal of magnetic resonance imaging : JMRI·2021

関連する実験動画

Updated: Mar 29, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K

ルイ体の認知症

Zuzana Walker1, Katherine L Possin2, Bradley F Boeve3

  • 1Division of Psychiatry, University College London, London, UK; North Essex Partnership University NHS Foundation Trust, Epping, UK.

Lancet (London, England)
|November 24, 2015
PubMed
まとめ

レービー体型認知症は 高齢者の間で2番目に多い認知症で 診断が間違っています 最近の進歩は,診断を改善し,よりよい患者管理のために,根本的な病理を標的とした治療法を開発することに焦点を当てています.

さらに関連する動画

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K
Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

関連する実験動画

Last Updated: Mar 29, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K
Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

科学分野:

  • 神経学
  • 神経科学
  • 高齢者医療

背景:

  • 認知症は世界的な健康問題であり,アルツハイマー病は研究対象となっています.
  • ルイ体の認知症 (LBD) は,ルイ体の認知症とパーキンソン病の認知症を含む,65歳以上の個人に第二に最も多い退行性認知症です.
  • 発症率が高いにもかかわらず,LBDはしばしば診断不足と不適切な患者管理に苦しんでいます.

研究 の 目的:

  • ルイ体の認知症の診断と理解における最近の進歩をレビューする.
  • LBDの効果的な治療法を開発するための課題と将来の方向性を強調する.
  • 診断の正確性と標的治療の必要性を強調する.

主な方法:

  • 過去10年間の関連科学文献のレビュー
  • LBDの診断基準の精錬における進展の分析
  • LBDの診断におけるイメージングとバイオマーカーの役割の評価

主要な成果:

  • LBDの診断の正確さを高めるために大きな努力がなされています.
  • ルイ体の認知症とパーキンソン病の認知症の共通病理学が認められている.
  • 診断マーカーを特定し,病気のメカニズムを理解する上で進展がありました.

結論:

  • 診断の精度とバイオマーカーの開発は LBD にとって極めて重要です.
  • 将来の治療はLBDの病理的メカニズムをターゲットにする必要があります.理想的には前症候です.
  • LBDの病原性を明らかにすることは,病気を修正する治療法の開発に不可欠です.